Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of M207 vs Intranasal Zolmitriptan in Healthy Volunteers
NCT03708744Phase 1Completed
- Sponsor
- Zosano Pharma
- Start
- Nov 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ZP-Triptan in migraine (4 arms), sponsored by Zosano Pharma. Primary endpoint: Maximum Observed Plasma Concentration at 24 hours. Started Nov 2018; status: completed.
02
Drugs
ZP-Triptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03708744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708744.